Immunomodulatory effects of IL-12 released from poly-N-acetyl glucosamine gel matrix during schistosomiasis infection

被引:5
作者
Salem, Mohamed L. [1 ]
Shoukry, Nahla M. [2 ]
Zidan, Abdel-Aziz A. [1 ]
Vournakis, John [3 ]
机构
[1] Tanta Univ, Fac Sci, Immunol & Biotechnol Div, Dept Zool, Tanta, Egypt
[2] Suez Univ, Dept Zool, Fac Sci, Suez, Egypt
[3] Marine Polymer Technol Inc, Boston, MA USA
关键词
Cytokine; IL-12; Infection; Polymer; Slow release; Granuloma; Schistosoma mansoni; T-CELL RESPONSE; CANCER VACCINE; IMMUNE-RESPONSES; MANSONI; INTERLEUKIN-12; DELIVERY; EGGS; MICE;
D O I
10.1007/s10616-013-9620-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have reported recently that Interleukin-12 (IL-12) released from poly-N-acetyl glucosamine gel matrix (F2 gel/IL-12) is more effective than free IL-12 to enhance vaccination of mice with Schistosoma soluble worm antigen preparation. The aim of this study is to evaluate the effect of F2 gel/IL-12 on the inflammatory responses in mice undergoing schistosomiasis infection in absence of vaccination. To achieve this, mice undergoing Schistosoma mansoni infection or cured from this infection, after treatment with praziquantil (PZQ), were treated with subcutaneous injection of IL-12 for 3 consecutive days or once with F2 gel loaded with IL-12 (F2 gel/IL-12). The treatment was started on day 35 days after infection. For infection, mice were infected with 100 cercariae of S. mansoni using tail immersion method. We found that treatment with F2 gel/IL-12 induced significant decreases in the egg burden with a moderate reduction in the size of granuloma and decrease in the cellular granulomatous reaction in the lung as compared to infected mice treated with IL-12. These effects of F2 gel/IL-12 were more pronounced in infected mice previously treated with the anti-schistosomal drug PZQ. The total numbers of white blood cells in all treated mice showed similar profile. Treatment with IL-12 or F2 gel/IL-12, however, showed significant reduction in the number of mononuclear cells when compared with non-treated infected mice. In conclusion, this study showed the ability of IL-12 released from F2 gel to lower the inflammatory response to Schistosoma infection even in absence of vaccination.
引用
收藏
页码:667 / 675
页数:9
相关论文
共 22 条
[1]   Human schistosomiasis mansoni: Immune responses during acute and chronic phases of the infection [J].
Caldas, Iramaya Rodrigues ;
Campi-Azevedo, Ana Carolina ;
Alves Oliveira, Lucia Fraga ;
Soares Silveira, Alda Maria ;
Oliveira, Rodrigo C. ;
Gazzinelli, Giovanni .
ACTA TROPICA, 2008, 108 (2-3) :109-117
[2]   Comparison of poly-N-acetyl glucosamine (P-GlcNAc) with absorbable collagen (Actifoam), and fibrin sealant (Bolheal) for achieving hemostasis in a swine model of splenic hemorrhage [J].
Chan, MW ;
Schwaitzberg, SD ;
Demcheva, M ;
Vournakis, J ;
Finkielsztein, S ;
Connolly, RJ .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2000, 48 (03) :454-457
[3]  
CHEEVER AW, 1993, AM J PATHOL, V142, P699
[4]  
Christensen NO, 1984, TECHNIQUE USE ROUTIN
[5]   Host nutritional status as a contributory factor to the remodeling of schistosomal hepatic fibrosis [J].
Coutinho, EM ;
Barros, AF ;
Barbosa, A ;
Oliveira, SA ;
Silva, LM ;
Araújo, RE ;
Andrade, ZA .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2003, 98 (07) :919-925
[6]   Kinetics of interleukin-6 production after experimental infection of mice with Schistosoma mansoni [J].
Khalil, RMA ;
Hultner, L ;
Mailhammer, R ;
Luz, A ;
Moeller, J ;
Mohamed, AA ;
Omran, S ;
Dormer, P .
IMMUNOLOGY, 1996, 89 (02) :256-261
[7]  
Maitre N, 1999, CLIN CANCER RES, V5, P1173
[8]   NATURAL-KILLER-CELL STIMULATORY FACTOR (INTERLEUKIN-12 [IL-12]) INDUCES T-HELPER TYPE-1 (TH1)-SPECIFIC IMMUNE-RESPONSES AND INHIBITS THE DEVELOPMENT OF IL-4-PRODUCING TH CELLS [J].
MANETTI, R ;
PARRONCHI, P ;
GIUDIZI, MG ;
PICCINNI, MP ;
MAGGI, E ;
TRINCHIERI, G ;
ROMAGNANI, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (04) :1199-1204
[9]   Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2) [J].
Nguyen, CL ;
Salem, ML ;
Rubinstein, MP ;
Demcheva, M ;
Vournakis, JN ;
Cole, DJ ;
Gillanders, WE .
VACCINE, 2003, 21 (19-20) :2318-2328
[10]   Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response [J].
Nguyen, CL ;
Bui, JT ;
Demcheva, M ;
Vournakis, JN ;
Cole, DJ ;
Gillanders, WE .
JOURNAL OF IMMUNOTHERAPY, 2001, 24 (05) :420-429